# A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes

Study · id `cardio:ct-nct06542874` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06542874](<https://clinicaltrials.gov/study/NCT06542874>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06542874

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 448 participants.

## Technical summary

Registry record NCT06542874. Randomized; quadruple masking; primary purpose treatment. Start 2024-08-07 (actual); primary completion 2025-10-01 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 448 participants (enrolled count; ClinicalTrials.gov record NCT06542874, source copy `cardio:ctgov-nct06542874-2026-10-02`, retrieved 2026-10-26)
- Started: 2024-08-07 (actual) (ClinicalTrials.gov record NCT06542874, source copy `cardio:ctgov-nct06542874-2026-10-02`, retrieved 2026-10-26)
- Primary completion: 2025-10-01 (actual) (ClinicalTrials.gov record NCT06542874, source copy `cardio:ctgov-nct06542874-2026-10-02`, retrieved 2026-10-26)
- Completion: 2025-10-24 (actual) (ClinicalTrials.gov record NCT06542874, source copy `cardio:ctgov-nct06542874-2026-10-02`, retrieved 2026-10-26)
- Countries: United States; Bulgaria; Croatia; Germany; Greece; Hungary; Japan; Poland; Romania; Slovakia; Spain (ClinicalTrials.gov record NCT06542874, source copy `cardio:ctgov-nct06542874-2026-10-02`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06542874-2026-10-02`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes
- Condition: Type 2 Diabetes (T2D)
- Intervention (Drug): NNC0487-0111 subcutanous
- Intervention (Drug): Placebo (NNC0487-0111 subcutanous)
- Intervention (Drug): NNC0487-0111 oral
- Intervention (Drug): Placebo (NNC0487-0111 oral)
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial (`cardio:pubmed-42532079`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial (`cardio:pubmed-42532080`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: f86e9df47a47e18b089b49e456dc558850d875d62be4a52bf5593a97f462d6ab
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
